Mylan NV operates in the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Mylan NV with three other companies in this sector in UNITED STATES : Daiichi Sankyo Company Limited (2019 sales of $8.38 billion of which 93% was Prescription drugs), Regeneron Pharmaceuticals Incorporated ($7.86 billion of which 59% was EYLEA), and CSL Limited ($8.54 billion of which 84% was CSL Behring).

Sales Analysis. Mylan NV reported sales of $11.50 billion for the year ending December of 2019. This represents a very small increase of 0.6% versus 2018, when the company's sales were $11.43 billion. Despite this increase, sales are still below the level achieved in 2017, when Mylan NV reported sales of $11.91 billion. Sales of Rest of World saw an increase that was more than double the company's growth rate: sales were up 5.5% in 2019, from $3.04 billion to $3.21 billion. Not all segments of Mylan NV experienced an increase in sales in 2019: sales of Europe fell 3.1% to $4.05 billion.